Lexicon Pharmaceuticals, Inc
Lexicon Pharmaceuticals is a biopharmaceutical company dedicated to pioneering medicines that transform patients' lives through innovative science, including a unique application of gene science. They focus on developing therapies for various conditions, including neuropathic pain and cardiometabolic diseases, with a mission driven by patient needs and cutting-edge research.
Industries
Nr. of Employees
medium (51-250)
Lexicon Pharmaceuticals, Inc
2445 Technology Forest Blvd, 11th floor, The Woodlands, Texas 77381
Patents
Solid forms of (S)-1-((2′,6-bis(difluoromethyl)-[2,4′-bipyridin]-5-yl)oxy)-2,4-dimethylpentan-2-amine and salts thereof
US-12344596-B2
View DetailsPyrazolo[1,5]pyrimidine-based compounds and methods of their use to treat viral infections
US-11666575-B2
View DetailsCrystalline solid forms of N-(1-((2-(dimethylamino)ethyl)amino)-2-methyl-1-oxopropan-2-yl)-4-(4-(2-methyl-5-((2S,3R,4R,5S,6R)-3,4,5-trihydroxy-6-(methylthio)tetrahydro-2H-pyran-2-yl)benzyl)phenyl)butanamide and methods of their synthesis
US-10968192-B2
View Details
Solid forms of (S)-1-((2′,6-bis(difluoromethyl)-[2,4′-bipyridin]-5-yl)oxy)-2,4-dimethylpentan-2-amine and salts thereof
US-12344596-B2
View DetailsPyrazolo[1,5]pyrimidine-based compounds and methods of their use to treat viral infections
US-11666575-B2
View DetailsCrystalline solid forms of N-(1-((2-(dimethylamino)ethyl)amino)-2-methyl-1-oxopropan-2-yl)-4-(4-(2-methyl-5-((2S,3R,4R,5S,6R)-3,4,5-trihydroxy-6-(methylthio)tetrahydro-2H-pyran-2-yl)benzyl)phenyl)butanamide and methods of their synthesis
US-10968192-B2
View DetailsProducts
Sotagliflozin (SGLT1/2 inhibitor)
Clinical development program for an SGLT1/2 inhibitor with indications including heart failure; development stages listed from preclinical through approved in the public pipeline table.
Pilavapadin (AAK1 inhibitor)
Clinical development program for an AAK1 inhibitor being developed for diabetic peripheral neuropathic pain and postherpetic neuralgia as listed in the public pipeline.
LX9851
Clinical development program listed for obesity/weight management in the public pipeline.
INPEFA (marketed product reference)
Listed product in site navigation indicating marketed product availability (product details accessible via product page).
Sotagliflozin (SGLT1/2 inhibitor)
Clinical development program for an SGLT1/2 inhibitor with indications including heart failure; development stages listed from preclinical through approved in the public pipeline table.
Pilavapadin (AAK1 inhibitor)
Clinical development program for an AAK1 inhibitor being developed for diabetic peripheral neuropathic pain and postherpetic neuralgia as listed in the public pipeline.
LX9851
Clinical development program listed for obesity/weight management in the public pipeline.
INPEFA (marketed product reference)
Listed product in site navigation indicating marketed product availability (product details accessible via product page).
Services
Evaluate and respond to physician-submitted expanded access requests for investigational medicines, including clinical evaluation, supply assessment, and timelines for acknowledgement.
Negotiation and execution of collaborations, strategic alliances, and royalty/milestone arrangements for discovery, development, and commercialization.
Support and formal request processes for investigator-initiated studies, sponsorships, educational grants and charitable donations.
Point of contact and processes for receiving adverse event or product quality complaints and directing reports to regulatory authorities as appropriate.
Evaluate and respond to physician-submitted expanded access requests for investigational medicines, including clinical evaluation, supply assessment, and timelines for acknowledgement.
Negotiation and execution of collaborations, strategic alliances, and royalty/milestone arrangements for discovery, development, and commercialization.
Support and formal request processes for investigator-initiated studies, sponsorships, educational grants and charitable donations.
Point of contact and processes for receiving adverse event or product quality complaints and directing reports to regulatory authorities as appropriate.
Expertise Areas
- Clinical trial management
- Drug discovery and target identification
- Precision / gene-science approaches
- Cardiometabolic therapeutics
Key Technologies
- Gene-science–based discovery platform
- Target identification and validation
- Small-molecule inhibitor development
- Clinical development platforms (Phase I–III)
News & Updates
The latest event held on Thursday, June 5, 2025, where Lexicon participated.
Presented at the 85th Scientific Sessions of the American Diabetes Association on June 23, 2025.
Lexicon announced its participation in the upcoming ADA conference.
Lexicon announced its presentation at the Jefferies Healthcare Conference.
The study design was presented at the European Society of Cardiology Congress.
Lexicon released its financial results and business updates for Q1 2025.
The latest event held on Thursday, June 5, 2025, where Lexicon participated.
Presented at the 85th Scientific Sessions of the American Diabetes Association on June 23, 2025.
Lexicon announced its participation in the upcoming ADA conference.
Lexicon announced its presentation at the Jefferies Healthcare Conference.
The study design was presented at the European Society of Cardiology Congress.
Lexicon released its financial results and business updates for Q1 2025.